Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer
about
MiR-200c and HuR in ovarian cancerStabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?Bidirectional interconversion of stem and non-stem cancer cell populations: A reassessment of theoretical models for tumor heterogeneityPathophysiological role of guanylate-binding proteins in gastrointestinal diseasesβIII-Tubulin: biomarker of taxane resistance or drug target?Adrenomedullin in ovarian cancer: foe in vitro and friend in vivo?Guanylate binding protein-1 mediates EGFRvIII and promotes glioblastoma growth in vivo but not in vitro.Serum Protein Profile in Women With Pregnancy Morbidity Associated With Antiphospholipid Syndrome.Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burdenMicrotubules and their role in cellular stress in cancerIdentification of the first inhibitor of the GBP1:PIM1 interaction. Implications for the development of a new class of anticancer agents against paclitaxel resistant cancer cells.Herpes virus microRNA expression and significance in serous ovarian cancerβIII-tubulin: a novel mediator of chemoresistance and metastases in pancreatic cancerGuanine nucleotide-binding protein 1 is one of the key molecules contributing to cancer cell radioresistanceNek6 and Hif-1α cooperate with the cytoskeletal gateway of drug resistance to drive outcome in serous ovarian cancer.RanBPM expression regulates transcriptional pathways involved in development and tumorigenesis.Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxelAltered TUBB3 expression contributes to the epothilone response of mitotic cells.Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burdenGamma interferon-induced guanylate binding protein 1 is a novel actin cytoskeleton remodeling factor.hGBP-1 Expression Predicts Shorter Progression-Free Survival in Ovarian Cancers, While Contributing to Paclitaxel Resistance.Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxelClass III b-tubulin overexpression in gynecologic tumors: implications for the choice of microtubule targeted agents?Novel mutations involving βI-, βIIA-, or βIVB-tubulin isotypes with functional resemblance to βIII-tubulin in breast cancer.Guanylate-Binding Protein-1 protects ovarian cancer cell lines but not breast cancer cell lines from killing by paclitaxel.Use of Integrated Computational Approaches in the Search for New Therapeutic Agents.Hypoxia-inducible factor-2α (HIF-2α), but not HIF-1α, is essential for hypoxic induction of class III β-tubulin expression in human glioblastoma cells.An Emerging Role for Tubulin Isotypes in Modulating Cancer Biology and Chemotherapy ResistanceGuanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer.
P2860
Q21261258-11671819-73FC-40C3-900B-D3E0FCECE972Q26781365-088ABF3D-4274-461A-898B-D68DAEE2202EQ28066409-E8CF9B5E-AE53-434E-ABC6-2EA300C652D6Q28078361-0A7EAD1D-F810-400E-95C8-1DDE39052DCDQ28284878-5BE76394-186A-4634-8263-7371CD354F47Q28481667-BBCA5E17-8A66-43B3-8A5F-E005C2F362F8Q30277399-9EA53CAF-2ABC-406D-85DF-11CD81ABF44CQ33604935-40F3127F-7C3A-4C4B-8DEC-BD211784E101Q33628532-6FCBD381-D6FD-48F4-B9D4-663C64FC02B0Q33770927-358A0A69-7003-4A29-B364-9FA5E0F3777DQ34313834-56164064-D3F8-4F80-A9FD-80AA303F3DF1Q34654294-1CB9715B-2F1D-4E69-8E76-95C34A2BAB99Q35273536-6E9B9463-2987-4C35-9848-BDF0CF9F0DEDQ35713203-C6B285F4-754E-45AD-A07D-7A3F3B4363DBQ35929796-9B368667-5762-4371-91BF-74D61787E768Q36206487-B9BDE981-6A3A-4153-B0BF-276B6E39290BQ36460311-6B46895D-D70E-4887-983E-36E69C599B96Q36557893-B4F79B9E-F776-480A-BA77-366AE22F89E5Q36891437-ACE311A1-63B3-47EA-9D8B-62B1ADDB979CQ37546046-CAE5C469-BD1F-47E7-8E19-8A61BF41A909Q37580494-D6674B1B-99B8-4D73-A676-19105B68D0A5Q37625835-132E0B1A-4EDC-43AF-9137-89CC9FD9D789Q38069185-E0484BF6-AC51-4E15-B909-FF8041D323B0Q38726651-FA7EF13F-7B18-4216-9FC2-80B6AFEC92E3Q38748476-64BA4FED-731B-4F2D-B862-D762CABB6DEEQ38933291-511B5943-7FB7-4E60-898E-2865408B9666Q38954268-9F880914-90A9-487D-A4F8-673AF9918395Q39414846-1E206577-C095-409A-87D1-786A3EF75C4FQ47121717-C967AE36-5896-4E1D-BD19-F22C64CD463F
P2860
Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer
@ast
Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer
@en
Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer
@nl
type
label
Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer
@ast
Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer
@en
Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer
@nl
prefLabel
Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer
@ast
Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer
@en
Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer
@nl
P2093
P2860
P50
P356
P1476
Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer
@en
P2093
Enrica Martinelli
Lella Petrella
Marta De Donato
P2860
P304
P356
10.1002/JCP.22813
P407
P50
P577
2012-03-01T00:00:00Z